Alcon Reports Q2-2024 Net Sales of $2.5 Billion

Alcon reported Aug. 20 that its Q2-2024 net sales totaled $2.5 billion, a record quarter for the company and a 3 percent increase (+6 percent cc) over $2.4 billion in Q2-2023.

Surgical net sales for implantables, consumables, and equipment/other were $1.42 billion, a 3 percent increase over $1.38 billion in Q2-2023.

The company said implantables net sales were $464 million, a 6 percent increase, led by demand for advanced technology intraocular lenses in international markets.

Consumables net sales were $736 million, a 3 percent increase, driven by cataract and vitreoretinal consumables, particularly in international markets, and price increases.

Equipment/other net sales were $223 million, a 3 percent decrease, reflecting strong demand in international markets for cataract equipment, Alcon said.

Vision care net sales for contact lenses and ocular health totaled $1.06 billion, a 4 percent increase (+6 percent cc) over $1.02 billion in Q2-2023.

Alcon, a Swiss company with US headquarters in Fort Worth, Texas, maintained its full year guidance of $9.9 billion to $10.1 billion.